GeoVax Comments on Recent Vaccine Development Study Funded by the Gates Foundation
Research Article Describes Inadequate Funding Levels for Vaccines Against HIV, Malaria and Tuberculosis ATLANTA, GA, Sept. 19, 2018 (GLOBE NEWSWIRE) -- ...
Home » HIV
Research Article Describes Inadequate Funding Levels for Vaccines Against HIV, Malaria and Tuberculosis ATLANTA, GA, Sept. 19, 2018 (GLOBE NEWSWIRE) -- ...
ORLANDO, Fla., Aug. 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune Therapeutics", "IMUN" or ...
ORLANDO, Fla., Aug. 07, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) ("Immune" “IMUN” or ...
Rolling BLA Submission Starting as Early as the End of 2018 - FDA Provides Guidance on Ongoing Requirements VANCOUVER, Washington, ...
VANCOUVER, Washington, June 04, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announced today that results from a Phase 2b/3 trial ...
Data Provide Support for PRO 140 as long-acting, HIV-1 maintenance therapy VANCOUVER, Washington, May 24, 2018 (GLOBE NEWSWIRE) -- CytoDyn ...
ORLANDO, Fla., April 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the ...
VANCOUVER, Washington, Oct. 05, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody ...
ORLANDO, Fla., Sept. 06, 2017, IMUN, (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing ...
VANCOUVER, Washington, Aug. 21, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody ...
VANCOUVER, Washington, Jan. 11, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of ...